Neuropathic corneal pain was significantly reduced after 12 weeks of treatment with urcosimod in a phase 2 trial, according to a press release from Okyo Pharma.
The FDA granted urcosimod, formerly called OK-101, fast track designation in May.
Topline data of 18 patients showed that those treated with 0.05% urcosimod for 12 weeks had a change in mean pain score of 5.5 (P = .025) while those in the placebo group had a mean change of 2.75 (P = .035). Moreover, 75% of those who received urcosimod had an improvement (Read more...)